Rentschler Biotechnologie GmbH, who is a leading contract manufacturing organization for the production and development of biopharmaceuticals, announced that it is going to invest €24 million to build a Twin system with two 3,000 Liters stainless steel bioreactors, mostly targeting market supply at the Rentschler‘s site in Laupheim, in Germany. The Twin system it is expected to be operational, in early 2017.

This Twin system is designed for running two major bioreactors in parallel with one shared downstream processing unit, providing higher throughput while reducing incremental labor costs involved.

The Twin system integrates well into the existing 3,000 Liters GMP line and will more than double the production capacities for cell culture-derived proteins. The Twin system is helpful in running cell culture processes in fed-batch mode with a very high output in a single suite.

Chief Business Officer at Rentschler, Frank Ternes said that the expansion will increase their market awareness and strengthen their global competitiveness of being a contract manufacturing organization partner of first choice all the way down from early clinical trials up to approval and also market supply to offer with a wide range of manufacturing technologies.

Rentschler in the last few years has been heavily investing in single-use technology. Recently it had announced that it will add a new 2,000 liter single-use bioreactor. Nonetheless, manufacturing in stainless steel is far from being outdated. Rentschler is witnessing a high demand for stainless steel bioreactor capacity, mostly for market supply, but also for late clinical phases. The criteria for selection of bioreactor includes the expected volume requirements, the characteristics of the product to be manufactured, competitive pricing due to optimal technological fit, the required flexibility and the approval phase.

Rentschler is a CMO with more than thirty-five years of proven track record in biopharmaceuticals. The company focuses on the application of mammalian cell lines, and it covers the production and development of recombinant proteins in compliance with international GMP standards.